Idelalisib was the first-in-class oral phosphatidylinositol 3-kinase (PI3K) inhibitor approved for the treatment of cancer, specifically for the therapy of relapsed CLL and FL [34]. This evidence concerns the gene PIK3CD and B-cell chronic lymphocytic leukemia.